THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha ® (evolocumab) to include ...
Repatha is the Only PCSK9 Inhibitor to Significantly Reduce the Risk of First CV Events in High-Risk Primary Prevention ...
THOUSAND OAKS, Calif., Oct. 6, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the launch of AmgenNow, a new direct-to-patient program starting with Repatha ® (evolocumab). This follows ...
(RTTNews) - Amgen (AMGN) announced detailed findings from its Phase 3 VESALIUS-CV clinical trial, revealing that Repatha (evolocumab) significantly reduces major adverse cardiovascular events (MACE) ...
Repatha VESALIUS-CV Trial Met Dual Primary Endpoints Demonstrating Reduction in CV Events in High-Risk Patients Who Have Never Had a Heart Attack or Stroke Real-World Evidence from the Repatha-CE ...
Amgen Canada announced today that the Governments of Ontario and Quebec have expanded public reimbursement of Repatha® (evolocumab injection) for eligible patients following an acute coronary syndrome ...
Most Medicare drug plans cover Repatha (evolocumab). This includes stand-alone Part D prescription drug plans and Medicare Advantage plans that include prescription drug coverage. Doctors prescribe ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results